Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonucleoprotein PTB-binding 1 (RAVER1) is a widely expressed, multidomain RNA-binding protein that forms complexes with the polypyrimidine tract-binding protein (PTB/hnRNPI) and with the cytoskeletal proteins vinculin/metavinculin and α-actinin, localizing both to the nucleus and microfilament attachment sites[2]. RAVER1 modulates alternative RNA splicing by acting as a co-repressor with PTB, especially important in tissue-specific splicing regulation such as that of tropomyosin in smooth muscle[1][3][4]. Structurally, RAVER1 contains three RNA recognition motifs (RRMs) and interacts with both nuclear and cytoskeletal compartments, coordinating aspects of RNA processing and microfilament anchoring[2]. Recent studies highlight its roles in oncogenesis and tumor cell growth, possibly through effects on splicing regulation and RNA metabolism[4]. No drugs are currently known to target RAVER1, and it is not established as a direct therapeutic target or biomarker at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleoprotein PTB-binding 1 (RAVER1).